Award Timing Disclosure |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 |
Jan. 06, 2025
USD ($)
shares
$ / shares
Rate
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing Disclosures [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing MNPI Disclosure | The Compensation Committee does not have a policy prohibiting the grant of share options, RSUs or other equity awards during periods in which there is material nonpublic information about our Company, including (1) outside a “trading window” established in connection with the public release of quarterly financial results, or (2) at any time during the four business days prior to, or the one business day following, the filing of our periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. The Compensation Committee does not take material nonpublic information into account when determining the timing and terms of equity awards, and has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Equity awards may occasionally be awarded on an off-cycle basis, including to new hires. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing Method | Equity awards may occasionally be awarded on an off-cycle basis, including to new hires. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing Predetermined | true | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Award Timing MNPI Considered | false | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MNPI Disclosure Timed for Compensation Value | false | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Awards Close in Time to MNPI Disclosures, Table | Pursuant to Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information regarding awards granted to NEO on the following dates: •
Consistent with our historical timing on annual equity awards, we granted share options to the following NEO on January 6, 2025, which was four business days before the filing of a Current Report on Form 8-K with which the Company furnished a press release announcing the Company’s strategic priorities for the upcoming year.
(1) Indicates percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Michael Davidson, M.D. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Awards Close in Time to MNPI Disclosures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name | Michael Davidson, M.D. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Underlying Securities | shares | 670,467 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise Price | $ / shares | $ 25.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value as of Grant Date | $ | $ 8,931,566 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Underlying Security Market Price Change | Rate | (229.00%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||